# A Study to Characterize Encorafenib Plus Cetuximab as Rechallenge Treatment for BRAF V600E-mutant Metastatic Colorectal Cancer Patients After Previous Therapy With BRAF Inhibitors-based Combinations

> **NCT07178717** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Vall d'Hebron Institute of Oncology** · enrollment: 25 (estimated)

## Conditions studied

- Colo-rectal Cancer

## Interventions

- **DRUG:** Rechalange with bevacizumab + encorafenib

## Key facts

- **NCT ID:** NCT07178717
- **Lead sponsor:** Vall d'Hebron Institute of Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-10
- **Primary completion:** 2028-02
- **Final completion:** 2028-08
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2025-09-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07178717

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07178717, "A Study to Characterize Encorafenib Plus Cetuximab as Rechallenge Treatment for BRAF V600E-mutant Metastatic Colorectal Cancer Patients After Previous Therapy With BRAF Inhibitors-based Combinations". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07178717. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*